Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Aquasurge** is an ophthalmic lubricant eye drop formulation primarily used for the treatment of **dry eyes**. It contains **carboxymethylcellulose** (also known as sodium carboxymethylcellulose or carmellose), typically at 0.5% or 1% concentration (e.g., Aquasurge Max at 1%), which acts as an artificial tear substitute. The active ingredient mimics natural tears by providing lubrication, stabilizing the tear film, increasing tear retention time due to its high viscosity, and protecting the ocular surface from irritation caused by dryness, wind, sun exposure, prolonged screen use, or post-surgical recovery (e.g., after laser or cataract surgery). It also lubricates and rewets soft and rigid gas-permeable contact lenses. Aquasurge is manufactured by companies such as Ipca Laboratories Ltd and Akums Drugs & Pharmaceuticals Ltd, and is available over-the-counter in 5ml or 10ml bottles for topical ophthalmic use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aquasurge.